Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Dasatinib Monotherapy in AML Refractory to Venetoclax + Azacitidine
2023-505846-24-00Phase 2Suspended
- Sponsor
- Institut Paoli-Calmettes
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Primary endpoint: Objective response rate after 2 cycles of dasatinib. Started Dec 2023; status: suspended.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-505846-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505846-24-00.